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Ayahuasca is a beverage with psychoactive properties used in religious and ceremonial rituals by some 
religious groups. The main active components of ayahuasca are dimethyltryptamine and the harmala 
alkaloids with β-carboline structure acting as monoamine oxidase A inhibitors. This combination 
produces a pronounced activation of serotonergic pathways and presents potential interaction with other 
psychotropics. The objective of this study was to investigate the possible interactions between ayahuasca 
and agents employed in general anesthesia. The pharmacological interactions between ayahuasca and 
morphine or propofol were evaluated in mice using doses of 12, 120 and 1200 mg/kg (0.1 to 10 times 
the average dose consumed by humans in religious rituals). Ayahuasca alone showed an antinociceptive 
effect in the writhing and formalin tests, and intensified the analgesic effect of morphine in the hot plate 
test. Concerning the pharmacological interactions between ayahuasca and propofol, the results were 
opposite; ayahuasca intensified the depressant effect of propofol in the rotarod test, but decreased the 
sleeping time induced by propofol. These set of results showed the occurrence of some interactions 
between ayahuasca and the drugs morphine and propofol, possibly by both pharmacokinetics and 
pharmacodynamics mechanisms. 
Keywords: Ayahuasca. Analgesic effect. Pharmacological interactions. Morphine. Propofol. β-Carbolines.
INTRODUCTION
Ayahuasca is a beverage with psychoactive 
properties prepared by decoction of two Amazonian 
plants, the vine of Banisteriopsis caapi (Spruce ex Griseb.) 
CV Morton (Malpighiaceae) and the leaves of Psychotria 
viridis (Ruiz & Pav.) (Rubiaceae) utilized in ceremonial 
contexts of groups like Santo Daime, União do Vegetal, 
among others. The religious use of ayahuasca is legally 
accepted in Brazil and also occurs in the United States 
and Europe (Labate, Feeney, 2012). Participants generally 
meet two to three times per month for the realization of 
a religious cult and they consume one or two cups of 
ayahuasca brew at the beginning of the ritual, but the 
amount of ayahuasca taken in a session may vary among 
the individuals and depending on the concentration of the 
beverage (McKenna, 2004). There is no official statistics 
about ayahuasca misuse, but it is reported that its use has 
expanded on the last decades and it is present in at least 
38 countries (Labate, Feeney, 2012; Domínguez-Clavé et 
al., 2016).
The main active components of ayahuasca are N,N-
dimethyltryptamine (DMT) and the harmala alkaloids with 
β-carboline structure, harmine, harmaline, tetrahydro-
harmine (THH), and harmol, as well harmalol in trace 
amounts (Callaway, Brito, Neves, 2005). DMT is present in 
the leaves of P. viridis and, when taken orally, it is rapidly 
inactivated by monoamine oxidase A (MAO-A) in the 
bowel and liver, which is avoided with the combination of 
β-carbolines present in B. caapi acting as MAO inhibitors 
(MAOI) (McKenna, Towers, Abbott, 1984). DMT is a 
potent 5-HT1A, 5-HT2A and 5-HT2C receptor agonist and 
also interact with other molecular targets (Frecska, Bokor, 
Winkelman, 2016; Domínguez-Clavé et al., 2016). In 
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addition, THH is believed to act as selective inhibitor of 
serotonin reuptake (Frecska, Bokor, Winkelman, 2016). 
The result of this interaction is a pronounced stimulation 
of serotonergic pathways leading to possible therapeutic 
potential, but also to potential interactions with other 
central nervous system drugs (Domínguez-Clavé et al., 
2016).
The anxiolytic properties of ayahuasca are described 
both in preclinical and clinical studies (Santos et al., 2007; 
Santos et al., 2016) and may be related with its serotonergic 
activity. According to information from members of the 
ayahuasca groups, it is a common procedure to drink a 
glass of ayahuasca before surgery to reduce anxiety and 
promote calmness (R. Guiso, personal communication), 
which makes relevant to evaluate possible interactions 
between the beverage and agents used in anesthesia. It is 
noteworthy that there is no medical literature assessing 
the safety of anesthetic procedures in patients who use 
ayahuasca. 
It was shown that ayahuasca components interfere 
with cerebral levels of monoaminergic and aminoacidergic 
neurotransmitters, including GABA (Castro-Neto et 
al., 2013). Since some selective inhibitors of serotonin 
reuptake, antipsychotics and other psychotropics 
are metabolized by CYP2D6 that also metabolizes 
harmine and harmaline, the concomitant use of these 
substances may be problematic and should be avoided 
(Callaway, Grob, 1998; Callaway, 2005; Jiang et al., 
2013). Moreover, it is known that MAOI may increase the 
depressant and analgesic effects of morphine (Kitanaka, 
Kitanaka, Takemura, 2006; Stockley, 2007), but there 
is no information of possible interactions with MAOI 
and propofol (Micromedex, 2016). In this study, mice 
were pretreated with ayahuasca and then treated with 
morphine or propofol to verify a possible pharmacological 
interaction among these agents. 
MATERIAL AND METHODS 
Animals 
Male Swiss mice, 3-4 months of age, weighing 30-50 
g, were obtained from the Department of Psychobiology, 
UNIFESP. The animals were kept in an isolated room 
with a light/dark cycle of 12 h (7:00 a.m.–7:00 p.m.) at 
constant temperature (23 ± 2°C) and fed ad libitum, except 
during testing. At the conclusion of the experiments, 
the animals were euthanized in a CO2 chamber. For the 
experiment of intestinal transit, the mice were killed by 
cervical dislocation. This study was approved by the Ethics 
Committee of UNIFESP (protocol 1494/06) following the 
standards recommended by the “International Guiding 
Principles for Biomedical Research Involving Animals” 
Geneva, 1985. 
Drugs, reagents and the preparation of ayahuasca 
liophilizate 
Commercial samples of propofol (Propovan®) and 
morphine sulfate (Dimorf®) were donated by Cristália 
Laboratory (São Paulo, Brazil). Acetic acid, charcoal, gum 
arabic and formaldehyde were purchased from Labsynth 
(São Paulo, Brazil). Propofol and morphine were diluted 
in saline and administered by intraperitoneal route.
The sample of ayahuasca (AYA) was produced 
in Manaus (Brazil) and donated by the Associação 
Benevolente Luz de Salomão according to the ritualistic 
protocol of this religion. The sample was concentrated and 
lyophilized (yield of 12%). A glass of 70 mL of ayahuasca 
(average volume ingested during rituals of this entity) was 
dried producing 8.4 g of solid. Therefore, a man of 70 kg 
(middle-weight) receives the equivalent of 120 mg/kg (8.4 
g/70 kg). This dose was chosen as the median unitary dose 
(1X). Doses equivalent to 0.1X (12 mg/kg), the ritualistic 
1X (120 mg/kg) and 10X (1200 mg/kg) were chosen for 
testing in order to increase the chances to observe the 
behavioral effects, since humans and rodents possess 
different metabolism, making the dosage transposition 
complicated. 
Determination of the active constituents
The main active constituents found in ayahuasca 
(dimethyl t ryptamine,  harmine,  harmal ine  and 
tetrahydroharmine) were determined as previously 
described by Pires et al. (2009a).
In summary,  the fol lowing procedure was 
performed: a sample solution containing the ayahuasca 
sample (0.5 mL), borate buffer (3.0 mL, pH 9.0) and the 
internal standard diphenhydramine (100 μL of a solution 
of 1.0 mg/mL) was loaded onto a solid-phase extraction 
C18 cartridge mounted on a vacuum manifold and 
conditioned with methanol (2.0 mL), deionized water 
(1.0 mL) and borate buffer (pH 9.0, 2.0 mL). The loaded 
cartridge was further washed with deionized water (1.0 
mL) and a solution of acetonitrile-water (1:9, 1.0 mL). 
After drying the cartridges under full vacuum for 7 min, 
the elution of analytes was performed with methanol 
(2.0 mL). Then, 1 μL of this solution was injected in 
a Agilent gas-chromatograph, model 6890, equipped 
with a nitrogen–phosphorous detector and a 7683 series 
automatic injector (Little Falls, DE, USA). The analytes 
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were identified based on a comparison of its relative 
retention time with the corresponding values of standards 
assayed in the same chromatographic run. Quantification 
was based upon the ratio of the integrated peak area to 
the internal standard.
Initial pharmacological screening
G r o u p s  o f  f i v e  m i c e  e a c h  w e r e  t r e a t e d 
intraperitoneally (i.p.) or orally (p.o.) by gavage with 
doses of 12, 120 and 1200 mg/kg of ayahuasca. The 
controls received the vehicles saline (i.p.) or water (p.o.). 
The animals were observed at intervals of 30 min for 4 h 
following treatment according to the protocol routinely 
employed by our group (Pires et al., 2009b; Bezerra et 
al., 2010). We observed the presence or absence or several 
signs, such as tremor, palpebral ptosis, muscular tonus, 
locomotor activity, ataxia, stereotypy, miction, defecation, 
among others. This experiment was used to establish the 
doses for subsequent tests and to disclose an initial profile 
of ayahuasca activity.
Tests to evaluate interaction between ayahuasca 
and propofol
A possible interaction between ayahuasca and 
propofol was evaluated in two behavioral tests: rotarod – to 
assess the motor coordination; and sleeping time – sedative 
/ hypnotic effect. The doses of propofol employed in each 
test were chosen based on literature data and pilot studies 
(data not shown).
Rotarod test
The performance of mice was measured by 
evaluating the time they remained on the rotating bar of 
the rotarod apparatus (AVS Project, Brazil) at a constant 
speed of 12 rpm. The animals were previously selected 24 
h before by eliminating those that could not stay on the bar 
for 60 s (Bezerra et al., 2010). First, we evaluated the effect 
of ayahuasca (120 and 1200 mg/kg, p.o.) or propofol (25, 
50 and 100 mg/kg, i.p.) isolated on the motor coordination 
of mice (n=5/group; pilot study). Then, groups of ten mice 
treated p.o. with water (control) or ayahuasca 1200 mg/
kg, 30 min before propofol (100 mg/kg) or saline (both 
i.p.) were evaluated on the rotarod apparatus at the times 
0 (basal), 30, 60 and 120 min. The dose of 1200 mg/kg of 
ayahuasca was chosen in order to increase the chance of 
observing propofol-ayahuasca interaction, since neither 
120 nor 1200 mg/kg affected the mice motor coordination 
per se.
Sleeping time test 
The doses of propofol were chosen based on pilot 
study and those described in the literature (Anwar, Abdel-
Rahman, 1998; Xu, Duan, Zeng, 2004). At the pilot study, 
the sleeping time was evaluated for mice treated i.p. with 
several doses of propofol (n=5/group). Then, groups 
of 7-10 mice each were pretreated (p.o.) with water 
(control) or ayahuasca (120 and 1200 mg/kg) followed by 
treatment with propofol (140 or 175 mg/kg, i.p.) 30 min 
later. The latency time (time elapsed between propofol 
administration and the loss of the righting reflex) and the 
sleeping time (time required for the animal to recover the 
righting reflex) were recorded (Bezerra et al., 2010).
Tests to evaluate interaction between ayahuasca 
and morphine
Three tests were employed to assess both a possible 
antinociceptive action of ayahuasca and its possible 
interaction with morphine. A fourth test evaluated the 
effects of morphine, ayahuasca and their interaction on 
intestinal transit.
Hot plate test
Groups of 7-10 mice each were treated p.o. with 
water (control) or ayahuasca (120 and 1200 mg/kg) and 
after thirty minutes treated by i.p. route with morphine 
(10 mg/kg) or saline and then evaluated at 0 (basal), 30, 
60, 120 and 240 min according to Pires et al. (2009b). 
Each mouse was placed individually on a hot plate (Ugo 
Basile, Italy) maintained at 55 ± 1 °C, and the elapsed 
time required for the animal to produce the characteristic 
responses to painful stimuli, such as jump or licking their 
paws, was recorded. Thirty seconds was considered the 
cut-off time to avoid tissue damage. 
Acetic acid writhing test
Groups of 10 mice each were treated p.o. with water 
(control) or ayahuasca (120 and 1200 mg/kg). Thirty minutes 
later, morphine (1 mg/kg) or saline were administered i.p. 
After an additional 30 min, 0.8% acetic acid was injected 
(i.p.), and the number of writhings (contractions of the 
abdomen with distension of the hind legs) was counted over 
a period of 20 min (Pires et al., 2009b).
Formalin test 
In the first experiment, mice (n= 5-7 per group) were 
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treated p.o. with water (control), ayahuasca (12, 120 and 
1200 mg/kg) or morphine (10 mg/kg, i.p.). In the second 
experiment, mice (n= 7-9 per group) received ayahuasca 
120 mg/kg or water (p.o.) and 30 min later morphine (1 
mg/kg) or saline by i.p. route. In both experiments, the 
test consisted of the subplantar injection of 20 µL of 
formalin (2.5%) in the right rear paw 30 min after the last 
treatment. Behavior was then measured in two periods. 
The animals were observed to evaluate the reaction to 
pain, measured as the time spent licking the paw, during 
the first phase (neurogenic; 0-5 min) and the second phase 
(inflammatory; 15-35 min) (Pires et al., 2009b).
Intestinal transit test
Groups of five mice each, fasted for 24 h, were treated 
p.o. with water (control) or ayahuasca (120 and 1200 mg/
kg), and after 30 min with morphine (5 mg/kg) or saline by 
i.p. route. Thirty minutes later, mice were given 0.35 ml 
(p.o.) of an aqueous suspension of 10% activated charcoal 
in 5% gum arabic. Fifteen minutes later, each animal was 
killed by cervical dislocation, the small intestine removed 
and the distance that the charcoal had traveled from the 
pylorus was measured and expressed as the percentage of 
the total length of the small intestines (Pires et al., 2009b).
Statistical analysis
The results are expressed as the mean ± standard 
error of mean (SEM). One-way ANOVA followed by 
Duncan’s test was employed to evaluate data with normal 
distribution: writhes, formalin, intestinal transit and 
sleeping time tests. Hot plate test (repeated measure) 
was analyzed by two-way ANOVA followed by Newman 
Keuls test. Motor coordination was analyzed by the 
Kruskal-Wallis followed by Mann-Whitney test after 
found a non-normal distribution. A level of significance 
of 5% (p<0.05) was adopted.
RESULTS
Determination of active constituents
Tetrahydroharmine (1.67 mg/mL) was the major 
constituent found in the ayahuasca sample followed by 
dimethyltryptamine (0.38 mg/mL), harmine (0.32 mg/mL) 
and harmaline (0.12 mg/mL).
Initial pharmacological screening with ayahuasca
Intraperitoneal doses of 120 mg/kg and 1200 mg/
kg of ayahuasca, under qualitative observation, produced 
decrease in locomotion and grooming, and increase of 
sensibility of mice to sound. Intense tremor was observed 
in the mice treated with 1200 mg/kg. These alterations 
did not occur with the oral route or were induced in minor 
intensity. No death was observed.
Rotarod test
The pilot study with ayahuasca and propofol 
isolated showed that ayahuasca at 120 and 1200 mg/kg or 
propofol at 25 and 50 mg/kg did not interfere with mice 
motor coordination, but propofol at dose of 100 mg/kg 
reduced the time on rota rod (data not shown). Further, we 
evaluated the effect of ayahuasca 1200 mg/kg and Propofol 
100 mg/kg isolated and in association. 
As can be seen in Figure 1, ayahuasca 1200 mg/
kg, by oral route, did not interfere with mice’s capacity to 
maintain themselves on the rotating bar. On the other hand, 
propofol (100 mg/kg, i.p.) greatly reduced the performance 
of the animals as all of them fell from the rod in less than 
20 s at 15 min after drug administration, but this effect was 
short-lived as the mice recovered the performance 15 min 
later (at 30 min measure). Furthermore, the group treated 
with ayahuasca + propofol presented motor incoordination 
at 15 and 30 min, when the effect was no more present on 
propofol group.
Sleeping time
The pilot study showed that propofol at doses 
between 100 and 200 mg/kg was able to induce sleep in 
mice (data not shown). As seen in Figure 2 the latency 
time to sleep was similar among the groups administered 
with propofol (140 and 175 mg/kg, i.p.). Ayahuasca (120 
and 1200 mg/kg, p.o.), somewhat decreased propofol 
sleeping time, although significance was reached only with 
the dosage of 120 mg/kg of ayahuasca plus 175 mg/kg of 
propofol. However, this effect was not confirmed with the 
larger dose of ayahuasca (1200 mg/kg).
Hot plate test
As can be seen in Figure 3, morphine induced the 
expected antinociceptive effect in mice at 30 min when 
compared with the basal latency, although this effect did 
not reach significance in the following measurements. 
Ayahuasca alone (120 and 1200 mg/kg, p.o.) did not 
change the response time of mice to the hot plate test. The 
association of ayahuasca (1200 mg/kg) plus morphine (10 
mg/kg) was able to induce the antinociceptive effect at 
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30, 60 and 120 min of observation, while the association 
with the dose of 120 mg/kg only reached significance at 
120 min. Additionally, the association of ayahuasca (both 
doses) with morphine significantly increased the latency 
time at 120 min compared with morphine group or with 
ayahuasca alone (columns 5 and 6, Figure 3). 
Acetic acid writhing test 
Morphine (1 mg/kg, i.p.) significantly reduced 
the numbers of writhes induced by acetic acid when 
compared to control mice (Figure 4). Ayahuasca (120 mg/
kg, p.o.) produced no effect per se and did not interfere 
with the morphine analgesia. However, ayahuasca (1200 
mg/kg, p.o.) produced a significant reduction of writhes 
(65%) when compared to control, and the association of 
ayahuasca 1200 mg/kg plus morphine 1 mg/kg showed 
the most potent analgesic effect (column 6 of Figure 4).
Formalin test 
Figure 5a shows that 10 mg/kg of morphine 
FIGURE 1 - Effect of ayahuasca (AYA, 1200 mg/kg, p.o.) isolated or in association with propofol (PRO, 100 mg/kg, i.p.), on the 
performance time of mice on the rotating bar. Results are expressed as the mean ± SEM (n=10). (*) p<0.05: statistically different 
from control; (#) p<0.05: statistically different from AYA 1200. Kruskal-Wallis followed by Mann-Whitney.
FIGURE 2 - Effect of ayahuasca (AYA, 120 and 1200 mg/kg, p.o.) on the latency time and sleeping time produced by propofol 
(PRO, 140 and 175 mg/kg, i.p.) in mice. Results are expressed as the mean ± SEM (n=7-10). (*) p<0.05: statistically different from 
group water + propofol 175 mg/kg. ANOVA followed by Duncan’s test.
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(i.p.) significantly decreased paw licking during the 
1st and 2nd phases by, respectively, 74 and 99%. The 
groups of mice treated p.o. with 12, 120 or 1200 mg/
kg of ayahuasca also showed significant dose-response 
decrease in the number of writhes in the first phase by, 
respectively, 35%, 42% and 75% in relation to the control 
group. On the other hand, measures taken at the second 
phase revealed that only the largest dose of ayahuasca 
(1200 mg/kg) produced a significant effect (reduction 
of 95%).
FIGURE 3 - Effect of ayahuasca (AYA, 120 and 1200 mg/kg, p.o.) associated with morphine (MOR, 10 mg/kg, i.p.) on the latency 
time of mice responding to the thermal stimulus. Results are expressed as the mean ± SEM (n=7-10). (*) p<0.05: statistically 
different from control; (#) p<0.05: statistically different from corresponding basal; (**) p<0.05: statistically different from morphine; 
(&) p<0.05: statistically different from corresponding dose of ayahuasca at the same observation time. 2-way ANOVA followed 
by Newman Keuls test.
FIGURE 4 - Effect of ayahuasca (AYA, 120 and 1200 mg/kg, p.o.) and its association with morphine (MOR, 1 mg/kg, i.p.) on the 
number of writhes induced by acetic acid (0.8%, i.p.). Results are expressed as the mean ± SEM (n=10). (*) p<0.05: statistically 
different from control; (#) p<0.05: statistically different from AYA 120. ANOVA followed by Duncan’s test.
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Figure 5b shows the results of the combination of the 
sub-effective dose of morphine and ayahuasca. Morphine 
(1 mg/kg, i.p.) alone did not diminish significantly the 
licking time on the first phase, while ayahuasca alone (120 
mg/kg, p.o.) or in combination with morphine (1 mg/kg) 
caused a reduction in paw licking during the first phase 
by 30% and 38%, respectively. There was no difference 
among the groups in the second phase, although the mice 
of morphine group showed a tendency of reduction (34%) 
on paw licking response.
Intestinal transit test
Morphine (5 mg/kg, i.p.), as expected, reduced 
intestinal motility by about 60%, as shown in Table I. Both 
dosages of ayahuasca were not able to significantly alter 
intestinal transit or either to interfere with morphine effect.
DISCUSSION
Several interactions between drugs and herbal 
FIGURE 5 - Effect of ayahuasca and morphine on the time that mice spent licking the paw after formalin 2.5% subplantar injection. 
A) Ayahuasca (AYA, 12, 120 and 1200 mg/kg, p.o.) and morphine (MOR, 10 mg/kg, i.p.) B) Ayahuasca (AYA, 120 mg/kg, p.o.), 
morphine (MOR, 1 mg/kg, i.p.) and the respective groups of association. Results are expressed as the mean ± SEM (A: n=5-7; 
B: n=9-10). (*) p<0.05: statistically different from control; (#) p<0.05: statistically different from AYA 12 and AYA 120. ANOVA 
followed by Duncan’s test.
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medicines have been reported, such as Hypericum 
perforatum and Ginkgo biloba (Fugh-Berman, 2000; 
Roby et al., 2000; Umegaki et al., 2007) and with 
foods, such as the juices of grapefruit or apples (Farkas, 
Greenblatt, 2008; Nowack, 2008), which interfere with 
the P450 enzyme system. The MAOI β-carbolines present 
in ayahuasca interfere with the absorption and metabolism 
of MAO substrates, but the effect of ayahuasca on drugs 
metabolized by other enzyme system (as P450) is poorly 
known. It was hypothesized that harmaline can alter the 
metabolic route of 5-methoxy-N-N-dimethyltryptamine 
(5-MeO-DMT), an analogue of DMT, leading to CYP2D6 
metabolism (alternative route) and increasing the 
production of bufotenine which seems to be more active 
than 5-MeO-DMT (Jiang et al., 2013; Halberstadt, 2016). 
However, 5-MeO-DMT is scarcely present in ayahuasca; 
it was found in trace amounts in some studies, but it was 
not detectable in most studies with different ayahuasca 
preparations (McKenna, 2004; McIlhenny et al, 2009; 
Pires, Oliveira, Yonamine, 2010). Nevertheless, the 
existence of an alternative route for DMT metabolism 
under MAO inhibition by β-carbolines was previously 
reported (Riba et al., 2012). 
The contents of β-carbolines and DMT in different 
ayahuasca samples may vary considerably depending 
on the species and proportion of parts used, method 
of preparation, time cooking, among other aspects 
(Rivier, Lindgren, 1972; McKenna, 2004; Callaway, 
Brito, Neves, 2005; Callaway, 2005). It is known that 
several species morphologically similar are employed 
on the tea preparation with alkaloid profiles very distinct 
(Callaway, 2005; Pires, Oliveira, Yonamine, 2010). Most 
samples of ayahuasca contain predominant amounts 
of harmine and tetrahydroharmine, while harmaline, 
harmalol, harmol and other β-carbolines are found in 
low concentration (Callaway, 2003). The concentrations 
of DMT and β-carbolines from the sample of ayahuasca 
used in this study are consistent to those already cited in 
the literature (Callaway, Brito, Neves, 2005; Callaway, 
2005; McIlhenny et al., 2009; Pires, Oliveira, Yonamine, 
2010), except for harmine. It is known that additional 
tetrahydroharmine may be formed from harmine and 
harmaline during the ayahuasca preparation (Callaway, 
2005; McIlhenny et al., 2009). In fact, tetrahydroharmine 
was the main alkaloid found in our sample. Although less 
studied than other β-carbolines, THH is also described 
as a weaker MAO inhibitor, but it can increase serotonin 
concentration by inhibiting serotonin reuptake and has 
longer half-life (Callaway, 2003; Domínguez-Clavé et 
al., 2016). 
Ayahuasca when administered as a lyophilizate to 
mice, either by intraperitoneal route or orally, revealed 
to be a safe drug since gross behavioral alterations 
were observed only with dose of 1200 mg/kg (10X 
the ritualistic), corroborating with previous studies in 
rodents (Pic-Taylor et al., 2015). In fact, ayahuasca is 
considered safe when used alone in the religious contexts 
(McKenna, 2004; Gable, 2007). However, the association 
of any psychotropic drugs must be considered with 
caution, including plants. Leak (2000) warns that the 
use of Hypericum perforatum, Piper methysticum and 
Valeriana officinalis during the perioperative period may 
affect anesthesia. It is suggested that the anesthesiologists 
should ask their presurgical patients about any medications 
they are taking, including herbal supplements and other 
alternative substances, and should decide about the 
discontinuation of the supplements when necessary, since 
these products can interfere with anesthesia and potentially 
cause complications during surgery (Kaye et al., 2007; 
Whinney, 2009; Abe et al., 2014).
The results of this study suggest an interaction 
between ayahuasca (at doses of 1 to 10 times the used 
in rituals) with morphine and propofol, verified by the 
modification of the isolated effects of these drugs. The 
dose of 12 mg/kg of ayahuasca (0.1X the ritual) was 
not evaluated in association with morphine or propofol 
because it presented only minor effects. Ayahuasca at 
the dose of 1200 mg/kg was able to increase the effect of 
propofol in the rotarod test and to decrease the propofol-
induced sleeping time. The results obtained in the 
interaction of ayahuasca with propofol seem contradictory, 
i.e., increased incoordination and decreased sleeping 
time. However, this result agrees with the personal 
information of ayahuasca users who report that the 
decoction produces body relaxation, but induces lack of 
sleep. Ayahuasca, as a MAOI, increases the central levels 
TABLE I - Effect of ayahuasca (120 and 1200 mg/kg, p.o.) and its 
association with morphine (5 mg/kg, i.p.) in the distance traveled 
by activated charcoal in the small intestine (percentage of the 
total length). Results are expressed as the mean ± SEM (n=5)
Treatment and doses (mg/kg) Intestinal transit (%)
Control (water + saline) 73.1 ± 8.4 
Water + morphine 5 29.5 ± 2.9*
Ayahuasca 120 + saline 55.9 ± 8.6
Ayahuasca 1200 + saline 64.7 ± 1.9
Ayahuasca 120 + morphine 5 27.3 ± 5.2*
Ayahuasca 1200 + morphine 5 29.6 ± 4.2*
* p<0.05: statistically different from control. ANOVA followed 
by Duncan’s test.
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of noradrenaline and serotonin which may increase the 
activation of the ascending reticular activating system. 
In our study, ayahuasca did not alter sleeping time and 
motor coordination per se, but altered the propofol 
effect. Propofol causes fast muscle relaxation but it is not 
considered a good hypnotic drug, instead, it is employed as 
a sedative and as an adjuvant in inducing and maintenance 
of anesthesia (McKeage, Perry, 2003). Since the effects 
of ayahuasca and propofol interaction were opposite on 
the two tests, we can hypothesize that these effects may 
be mediated by different pathways, but our current data 
is not enough to propose the mechanisms of interaction.
Furthermore, ayahuasca revealed to possess 
analgesic effect per se. Thus, the dose of 1200 mg/kg 
decreased the number of writhes of mice challenged with 
acetic acid and decreased the paw licking of mice in the 
first phase (0-5 min) on formalin test. In this respect it is 
interesting that extracts of Peganum harmala, containing 
high concentration of harmaline, showed antinociception 
in the formalin test (Monsef et al., 2004), corroborating 
with our data. The previous administration of 120 or 1200 
mg/kg of ayahuasca to mice prolonged the morphine 
analgesia as measured through the hot plate test. This data 
would suggest a synergic effect of ayahuasca, perhaps 
inhibiting the morphine metabolism. Clorgyline, a MAOI, 
potentiated morphine-induced antinociception in tail flick 
test, but not in the hot plate test (Kitanaka, Kitanaka, 
Takemura, 2006). On the other hand, ayahuasca was not 
able to increase morphine analgesia in formalin test, 
although it has been active by itself (Figure 5). Because 
ayahuasca per se was not active on thermal nociception 
and did not alter the intestinal transit, it is possible that 
ayahuasca acts by a non-opioid mechanism, possibly 
by anti-inflammatory process. Another hypothesis is 
that ayahuasca analgesic effect depend on the central 
serotonergic modulation and/or endogenous opioid release 
which are reached on specific time points.
The β-carbolines exert a plenty of neurophysiological 
effects such as competitive inhibition of monoamines 
uptake, inhibition of Na+-dependent ATPases, among 
others (for a review, see McKenna, 2004). Interestingly, 
harman and harmine attenuated some signs of naloxone-
precipitated morphine withdrawal syndrome (Aricioglu-
Kartal, Kayir, Uzbay, 2003), what corroborate with the 
hypothesis that these alkaloids may modulate the opioid 
system. The authors suggested that the beneficial effects 
may be mediated by imidazoline receptors, what was later 
evaluated by Miralles et al. (2005) that demonstrated the 
β-carbolines bind with high affinity to imidazoline I2B 
receptors. However, further studies are needed in order 
to evaluate the antinociceptive effect of ayahuasca in the 
presence and absence of antagonists to better elucidate its 
mechanism of action. Ayahuasca interactions with propofol 
in the antinociceptive tests were not evaluated because the 
analgesic effect after propofol acute administration is too 
short (Anwar, Abdel-Rahman, 1998; Rahman, Hashim, 
2011).
Taken together, the set of results showed that the 
oral pre-treatment with ayahuasca in doses from 1 to 10 
times the used in rituals (120-1200 mg/kg) modified some 
effects of intraperitoneal administration of morphine and 
propofol. The use of morphine and propofol by i.p. route 
in our study limits the translation of our results to humans 
since the intravenous administration leads to faster and 
more potent effects. However, some pharmacokinetic 
interactions cannot be discarded. For instance, the finding 
that ayahuasca increased and extended the effect of 
morphine on the hot plate suggests that ayahuasca may 
reduce its metabolism. 
In summary, the present study shows that the 
lyophilizate of ayahuasca decoction modified the 
analgesic effects of morphine in mice depending on 
the test employed. Furthermore, the muscle relaxant 
effect of propofol in the rotarod was prolonged, while 
its sedative effect seemed reduced. These data suggest 
that anesthetists should take some caution when using 
morphine or propofol in followers of ayahuasca cults 
undergoing surgical procedures. More studies are needed 
to better investigate the interactions between ayahuasca 
and morphine/propofol, and pharmacokinetic studies are 
suggested to address this question. 
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